Tempus AI downgraded by BofA Securities with a new price target
$TEM
Computer Software: Programming Data Processing
Technology
BofA Securities downgraded Tempus AI from Buy to Neutral and set a new price target of $60.00 from $45.00 previously
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 2/12/2025 | Outperform → Mkt Perform | William Blair | |
| 2/5/2025 | $58.00 → $74.00 | Buy | TD Cowen |
| 12/13/2024 | $60.00 | Outperform | Wolfe Research |
| 12/9/2024 | $74.00 | Buy | Guggenheim |
| 11/11/2024 | $45.00 → $65.00 | Buy → Hold | Stifel |
| 10/2/2024 | $45.00 → $60.00 | Buy → Neutral | BofA Securities |
| 8/12/2024 | $40.00 | Neutral | Piper Sandler |
| 7/9/2024 | $41.00 | Buy | BofA Securities |
Tempus AI, Inc. (NASDAQ:TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced a new collaboration with the Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL). The collaboration aims to develop and make available a real-world multimodal, deidentified FL data library in Lens - Tempus' data analytics platform - through which researchers may derive AI-driven insights to accelerate the development of FL treatments in an effort to improve patient outcomes. IFLI is committed
USA News Group News CommentaryIssued on behalf of Avant Technologies Inc. VANCOUVER, BC, Feb. 11, 2025 /PRNewswire/ -- USA News Group News Commentary – Weeks after the monumental $500-billion announcement of Project Stargate, which includes aims to transform healthcare, a growing number of health executives are seeing the promise of Artificial Intelligence (AI) in their industry. A recent poll from Deloitte found that 40% of health execs say generative AI (genAI) pays off for their businesses. Early in 2025, it's becoming clearer that genAI is revolutionizing diagnostics, enhancing treatment options, and personalizing patient care. Beyond Stargate's big players, a growing number of innovator
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i
144 - Tempus AI, Inc. (0001717115) (Subject)
SCHEDULE 13G/A - Tempus AI, Inc. (0001717115) (Subject)
8-K - Tempus AI, Inc. (0001717115) (Filer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
4 - Tempus AI, Inc. (0001717115) (Issuer)
William Blair downgraded Tempus AI from Outperform to Mkt Perform
TD Cowen resumed coverage of Tempus AI with a rating of Buy and set a new price target of $74.00 from $58.00 previously
Wolfe Research initiated coverage of Tempus AI with a rating of Outperform and set a new price target of $60.00
4 - Tempus AI, Inc. (0001717115) (Reporting)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13G - Tempus AI, Inc. (0001717115) (Subject)
SC 13D/A - Tempus AI, Inc. (0001717115) (Filed by)
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the fourth quarter and full year 2024 on Monday, February 24, 2025. The company will hold the earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 9601821 Domestic Dial-in Number: (888) 596-4144 International Dial-i
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Monday, November 4, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The company's conference call that was previously scheduled for November 7, 2024 has been canceled. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the
Tempus AI, Inc. (NASDAQ:TEM), a leader in artificial intelligence and precision medicine, today announced they will report financial results for the third quarter on Thursday, November 7, 2024. The company will hold the third quarter 2024 earnings conference call at 4:30 p.m. ET. The company's quarterly earnings will be released the same day. The call will feature Tempus Founder and CEO, Eric Lefkofsky, and Chief Financial Officer, Jim Rogers. The live audio webcast will be accessible through the events page of Tempus' Investor Relations website. Alternatively, the call can be accessed via the following: Conference ID: 7177136 Domestic Dial-in Number: (800) 715-9871 International Dial-in